FDA Accepts UGN-103 NDA, Sets June 2027 Decision Date
URGN has more than doubled off its 52-week low of $16.365.
Summary
The FDA accepted UroGen's NDA for UGN-103, a next-generation mitomycin formulation for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with a PDUFA action date of June 14, 2027. The filing rests on Phase 3 UTOPIA data showing a 77.8% complete response rate at three months and a 94.5% estimated probability of remaining event-free at six months among responders — consistent with the pivotal ENVISION trial behind ZUSDURI. This matters because UGN-103 is the intended successor to ZUSDURI, the company's growth engine that drove Q2 revenue of $72.5M and a 199% year-over-year increase. Acceptance is a procedural milestone, not an approval, and the decision is roughly eight months out; a complete response letter or delay would hit a story now built on ZUSDURI's ramp. Patent coverage on the RTGel-plus-mitomycin combination is expected to extend into July 2044.
At the time of this announcement, URGN was trading at $34.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $16.37 to $50.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.